Given the emergence of a number of redox-targeted therapeutics in the IBD field (e.g. hypoxia-inducible factor 1α (HIF-1α)-agonists/stabilizers or nuclear factor erythroid 2-related factor 2 (NRF2)/Kelch-like ECH-associated protein 1 (KEAP1) modulators), these novel treatments should be assessed in terms of effectiveness, safety, and tolerability at the individual patient level. Here, HIF1A is linked to inflammatory bowel disease.